RecruitingPhase 2NCT07192068

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

Studying Sarcoma of cervix uteri

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UNICANCER
Principal Investigator
Barbara PISTILLI, Dr
Gustave Roussy, VILLEJUIF
Intervention
Zanidatamab(drug)
Enrollment
105 target
Eligibility
18 years · All sexes
Timeline
2025 – 2030

Study locations (4)

Collaborators

National Cancer Institute, France · Jazz Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07192068 on ClinicalTrials.gov

Other trials for Sarcoma of cervix uteri

Additional recruiting or active studies for the same condition.

See all trials for Sarcoma of cervix uteri →

← Back to all trials